在间质性膀胱炎/膀胱疼痛综合征时膀胱颈狭窄的手术治疗

封面

如何引用文章

全文:

详细

绪论间质性膀胱炎/膀胱疼痛综合征（IC/PBS）的现代治疗方法不能实现长期临床缓解。

研究的目的。目的探讨膀胱颈经尿道切开手术（TUI）治疗对有间质性膀胱炎/膀胱疼痛综合征患者的临床疗效。

材料与方法。对间质性膀胱炎/膀胱疼痛综合征及经证实膀胱颈部狭窄的患者（n = 29）行膀胱颈部的经尿道切开手术。在手术治疗后1个月、3个月、6个月对手术结果进行评估。治疗效果评估采用 GRA（Global Response Assessment）量表、间质性膀胱炎/膀胱疼痛综合征症状量表（尿急症状评分）、排尿日记，通过分析，可以确定膀胱的功能容量，排尿频率和夜尿。疼痛采用视觉模拟评分法（VAS）进行评估。功能效率是通过尿动力学研究确定的，其中包括膀胱测量能力，最大流量，和残余尿量。将治疗结果与39例无膀胱颈狭窄征象的间质性膀胱炎/膀胱疼痛综合征患者进行比较。

结果：在膀胱颈经尿道切开手术后1个月和3个月GRA指标≥2的分别有96.5和72.4%。术后VAS、尿急症状评分、膀胱容量、最大排尿率、残余尿量、排尿频率、夜尿率等指标均有明显改善。

结论。这项前瞻性临床研究是首次研究膀胱颈狭窄女性间质性膀胱炎/膀胱疼痛综合征的病程。在膀胱颈部经尿道切开手术后1个月，96.5%的患者间质性膀胱炎/膀胱疼痛综合征症状减轻，无尿路感染及局部并发症发生。与此同时，72.4%的患者术
后3个月和68.9%的患者术后6个月都保持了这种效果。

作者简介

Vladimir Medvedev

Kuban State Medical University; Regional Clinical Hospital No. 1 named after prof. S.V. Ochapovsky; Rostov State Medical University

Email: medvedev_vl@mail.ru
ORCID iD: 0000-0001-8335-2578

Doctor of Medical Science, Professor, Chairman of the Department of Urology; Deputy Chief Physician for Urology, Head of the Urological Center of Scientific Research Institute; Professor of the Department of Urology and Human Reproductive Health (with a Course in Pediatric Urology-Andrology)

俄罗斯联邦, Krasnodar; Krasnodar; Rostov-on-Don

Igor Mihailov

Kuban State Medical University; Regional Clinical Hospital No. 1 named after prof. S.V. Ochapovsky

Email: miv67@yandex.ru
ORCID iD: 0000-0003-3724-2794

Doctor of Medical Sciences, Professor, Department of Urology; Doctor of the Oncourology Department 

俄罗斯联邦, Krasnodar

Sergey Lepetunov

Kuban State Medical University; Regional Clinical Hospital No. 1 named after prof. S.V. Ochapovsky; Rostov State Medical University

编辑信件的主要联系方式.
Email: Lepetunov@gmail.com
ORCID iD: 0000-0001-6657-1496

Assistant of the Department of Urology; Urologist; Postgraduate, Department of Urology and Human Reproductive Health (with a Course in Pediatric Urology-Andrology)

俄罗斯联邦, Krasnodar; Krasnodar; Rostov-on-Don

Yuriy Medoev

Regional Clinical Hospital No. 1 named after prof. S.V. Ochapovsky; Rostov State Medical University

Email: dadoev@list.ru
ORCID iD: 0000-0002-3726-0186

Urologist; Postgraduate, Department of Urology and Human Reproductive Health (with a Course in Pediatric Urology-Andrology)

俄罗斯联邦, Krasnodar; Rostov-on-Don

Mikhail Kogan

Rostov State Medical University

Email: dept_kogan@mail.ru
ORCID iD: 0000-0002-1710-0169

Doctor of Medical Science, Professor, Chairman of the Department of Urology and Human Reproductive Health (with a Course in Pediatric Urology-Andrology)

俄罗斯联邦, Rostov-on-Don

参考

  1. Hanno PM, Sant GR. Clinical highlights of the National institute of diabetes and digestive and kidney diseases / interstitial cystitis. Urology. 2001;57(6 Suppl 1):2-6. https://doi.org/10.1016/s0090-4295(01)01112-8.
  2. Gülpınar Ö, Esen B, Kayış A, et al. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37(1):257-262. https://doi.org/10.1002/nau.23284.
  3. Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65(4):654-658. https://doi.org/10.1016/j.urology.2004.10.071.
  4. Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulphate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810-815. https://doi.org/10.1097/01.ju.0000083020.06212.3d.
  5. Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J Urol. 1989;141(4):846-848. https://doi.org/10.1016/s0022-5347(17)41029-9.
  6. Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2005;171(6):2138-2141. https://doi.org/10.1097/01.ju.0000125139.91203.7a.
  7. Giannantoni A, Porena M, Costantini E, et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008;179(3):1031-1034. https://doi.org/10.1016/j.juro.2007.10.032.
  8. Медведев В.Л., Лепетунов С.Н. Ботулинический токсин в лечении интерстициального цистита // Вестник урологии. – 2017. – Т. 5. – № 3. – С. 68–78. [Medvedev VL, Lepetunov SN. Botulinum toxin A for the management of interstitial cystitis / bladder pain syndrome. Urology herald. 2017;5(3):68-78. (In Russ.)]. https://doi.org/10.21886/2306-6424-2017-5-3-68-78.
  9. Зайцев А.В., Шаров М.Н., Арефьева О.А., Пушкарь Д.Ю. Синдром болезненного мочевого пузыря / интерстициальный цистит: факторы прогноза клинического течения заболевания // Вестник урологии. – 2018. – Т. 6. – № 3. – С. 26–35. [Zaitsev AV, Sharov MN, Arefieva OA, Pushkar DYu. Interstitial cystitis/bladder pain syndrome: factors predicting the clinical course of the disease. Urology herald. 2018;6(3):26-35. (In Russ.)]. https://doi.org/10.21886/2308-6424-2018-6-3-26-35.
  10. Пушкарь Д.Ю., Касян Г.Р. Ошибки и осложнения в урогинекологии. – М.: ГЭОТАР-Медиа, 2017. – 377 с. [Pushkar’ DYu, Kasyan GR. Oshibki i oslozhneniya v uroginekologii. Moscow: GEOTAR-Media; 2017. 377 p. (In Russ.)].
  11. Глыбочко П.В., Коган М.И., Набока Ю.Л. Инфекции и воспаления в урологии. – М.: Медфорум, 2019. – 888 с. [Glybochko PV, Kogan MI, Naboka YuL. Infekcii i vospaleniya v urologii. Moscow: Medforum, 2019. 888 p. (In Russ.)].
  12. Петрос П. Женское тазовое дно. Функции, дисфункции и их лечение в соответствии с интегральной теорией / Пер. с англ. под ред. Д.Д. Шкарупы. 2-е изд. – М.: МЕДпресс-информ, 2016. – 396 с. [Petros P. The female pelvic floor. Function, dysfunction and management according to the Integral theory. Transl. from English ed. by D.D. Shkarupa. 2th ed. Moscow: MEDpress-inform; 2016. 396 p. (In Russ.)]
  13. Gillenwater JY, Wein AJ. Summary of the National institute of arthritis, diabetes, digestive and kidney diseases workshop on interstitial cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol. 1988;140(1):203-206. https://doi.org/10.1016/s0022-5347(17)41529-1.
  14. Lubeck DP, Whitmore K, Sant GR, et al. Psychometric validation of the O’Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001;57 (6 Suppl 1):62-66. https://doi.org/10.1016/s0090-4295(01)01126-8.
  15. Propert KJ, Mayer RD, Wang Y, et al. Responsiveness of symptom scales for interstitial cystitis. Urology. 2006;67(1):55-59. https://doi.org/10.1016/j.urology.2005.07.014.

版权所有 © Medvedev V.L., Mihailov I.V., Lepetunov S.N., Medoev Y.N., Kogan M.I., 2020

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##